The FDA got a vote of confidence from the Trump administration when it recommended increasing its budget in February – and yesterday its leader Scott Gottlieb explained to Congress some of
After just seven months, Scott Gottlieb has stamped his own imprint on the FDA and, so far, has confounded fears he would be unduly influenced by President Trump or the pharma industry.
It has been five years since Lexicon Pharma's type 1 diabetes therapy, Zynquista, was rejected by the FDA, and it may struggle to have a better outcome at its second attempt.
